Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Ovintiv Inc. (DE) (OVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Ovintiv Inc. (DE) — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Ovintiv Inc. (DE) trades at $66.75 (market cap $18.44B). The key difference: Ovintiv Inc. (DE) is far larger — about 19× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ovintiv Inc. (DE) pays a 1.8% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Ovintiv Inc. (DE) for 6 Days on average.
| MRVI | OVV | |
|---|---|---|
Market Cap | $972.90M | $18.44B |
Volume | 4,325,710 | 3,495,725 |
Sector | Health | Energy |
52-Week High | $9.00 | $66.97 |
52-Week Low | $2.83 | $35.97 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $22.77B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
OVV trades at $66.66, up 2.36% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing robust revenue growth. Recent news highlights expansion in Permian and Montney assets, share buybacks, and strong free cash flow generation, positioning the stock for potential upside.
The outlook for OVV is positive, driven by operational strength and strategic acquisitions, though risks include commodity price volatility and natural gas headwinds. With a consensus price target of $76.00 and no sell ratings, Wall Street sentiment remains bullish, offering a favorable risk-reward profile for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →
